Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (410)

« Back to Publications

Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response

Peralta Alvarez MP. et al, (2026), Vaccines, 14, 509 - 509

Rational Design of a Chimpanzee Adenoviral-Vector Vaccine Against Yellow Fever Through the Modification of Antigen Transmembrane Domains.

Ulaszewska M. et al, (2026), Vaccines (Basel), 14

Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines.

Hlaváč M. et al, (2026), Vaccines (Basel), 14

Biochemical profiling provides a low-cost and globally accessible method to detect falsified vaccines and insulin.

Brook J. et al, (2026), Sci Rep, 16

Replication-incompetent viral vaccine vectors ChAdOx1 and MVA as tools for evaluating T-cell responses to naturally processed antigens in vitro.

Nazki S. et al, (2026), Virus Res, 364

Developing the next-generation of adenoviral vector vaccines.

Sampson AT. et al, (2025), Hum Vaccin Immunother, 21

Vaccines against Lassa fever virus (VITAL): Phase 1 safety and immunogenicity studies of a Lassa fever vaccine, ChAdOx1 LassaJ, in healthy volunteers in the UK and Ghana

Curtis BI. et al, (2025), Journal of Interventional Epidemiology and Public Health, 8

Shear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosis.

Chen YC. et al, (2025), Blood, 146, 496 - 503

Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.

McLean RK. et al, (2025), NPJ Vaccines, 10

Priorities for rapid and cost-effective vaccines to improve outbreak responses.

Gilbert SC., (2025), PLoS Biol, 23

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Sanderson J. et al, (2025), EBioMedicine, 113

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults

Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734

Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.

Vatzia E. et al, (2024), NPJ Vaccines, 9

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine.

Wee EG-T. et al, (2024), Vaccines (Basel), 12

Load More

1
2
3
4
5
6
7
...
»